Ghassan Abou-Alfa

@MSKCancerCenter Medical Oncologist, liver, cholangiocarcinoma, gallbladder, biliary cancer specialist. Global healthcare specialist. Patients’ advocate.

[Ghassan Abou-Alfa @GABOUALFA]

How are you navigating immunotherapy decisions across the continuum of hepatobiliary cancer? We’ll be digging into the latest data and real-world clinical decision points in HCC and BTC in Denver this November. Join us! https://t.co/GsMfq3aI7b

[Ghassan Abou-Alfa @GABOUALFA]

How are you navigating immunotherapy decisions across the continuum of hepatobiliary cancer? We’ll be digging into the latest data and real-world clinical decision points in HCC and BTC in Denver this November. Join us! https://t.co/GsMfq3aI7b

[OncoDaily GI @OncoDailyGI]

Phase 3 EMERALD-3 results are now published in The Lancet Oncology.

In embolization-eligible HCC, STRIDE + lenvatinib + TACE improved PFS vs TACE alone:
• PFS: 13.0 vs 9.8 months (HR 0.70; p=0.0007)
• ORR: 37% vs 30%
• OS: 39.5 vs 34.7 months (HR 0.84; p=0.1814)

STRIDE + TACE also showed improvements in PFS and OS in descriptive analyses, but these comparisons could not be formally tested due to hierarchical testing.

Takeaway: EMERALD-3 met its primary PFS endpoint, supporting a STRIDE-based regimen as a potential new treatment option. Final OS follow-up is ongoing.

@GABOUALFA @s_tekumalla @oncodaily

👉 https://t.co/RREsgHE4iT

#OncoDaily #EMERALD3 #HCC

[PeerView @PeerView]

#Immunotherapy is moving into earlier stages of #HCC treatment. Watch this concise activity, presented by @GABOUALFA, to learn the latest updates from ASCO 2026! https://t.co/7JUhMhhMFB

[Ghassan Abou-Alfa @GABOUALFA]

EMERALD-3: a global, randomised, open-label, sponsor-blinded, phase 3 study - The Lancet Oncology https://t.co/lEJg99xt14

[Nagi El Saghir MD, FASCO, FACP @NagiSaghir]

Stay tuned for Best of ASCO #Lebanon JULY 10-11 at @AUBMC_Official Licensed by @ASCO / Advances in #Cancer @drhibamoukadem @RitaAssi4 @EileenMOReilly @GABOUALFA @Layalmahmasani

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

Today at #ASCO26: MSK early drug development specialist @YoninaMG shared her poster "First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0–49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01."

[Agrima Mian @AgrimaMianMD]

Moments like today at #ASCO26 remind you why oncology is such an extraordinary field. What an absolute privilege to witness advances like #RASOLUTE-302 in real time. #RAS_ON @MSK_DeptOfMed @RevMedicines @DanaFarber #mPDAC

[Michael May @MichaelMayMD]

Living through history! @EileenMOReilly @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk @ASCO

[OncLive.com @OncLive]

@EileenMOReilly of @MSKCancerCenter with an excellent overview of #KRAS targeting in #PancreasCancer at #ASCO26. A truly remarkable time with multiple strategies targeting RAS, opening new frontiers in treatment and thought about modulating the tumor microenvironment and potentials for combination strategies.

@Jonathanwlee23 @CentralParkWMD @drallysonocean @NBalmacedaMD

#MedEd
#Oncology

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

MSK research fellow @OrlaFitz10 shared her poster "Tracking genomic evolution in ERBB2-altered biliary tract cancer through longitudinal tumor profiling" during #ASCO26. @ASCO

[Michael May @MichaelMayMD]

Stop by poster board 155 to learn about clinical and genomic predictors of organotropism in pancreatic neuroendocrine carcinoma! @CentralParkWMD @FiyinfoluB @RadOncConnor @MSKCancerCenter @MSK_DeptOfMed @CpcrMsk

[Anirban Maitra @Aiims1742]

The preliminary program for @AACR 2026 Special conference on #PancreaticCancer in San Diego is now online. The abstract deadline is July 13th.
#AACRPan26
@PanCAN @letswinpc @lustgartenfdn @break_cancer
https://t.co/GErpStPZ7Q

[AACR @AACR]

Submit an abstract by July 13 for the AACR Conference on Pancreatic Cancer (Sept 25-28; San Diego), chaired by Andrew J. Aguirre, Florencia McAllister, Kenneth P. Olive, Eileen O’Reilly, Diane M. Simeone, and Colin D. Weekes.
https://t.co/mkjVIiZblJ
#AACRpan26 @EileenMOReilly

[Anirban Maitra @Aiims1742]

Technically MTAP loss and the resulting therapeutic vulnerability created is an example of “collateral lethality”.
https://t.co/RqSAf88UWp
A term first proposed by @RonDePinho
https://t.co/JwrIrnKnjp
However there may be an element of synthetic lethality here as well…(1/2)

[OncoDaily GI @OncoDailyGI]

AACR 2026 Pancreatic Cancer Conference Program Now Available - Anirban Maitra (@Aiims1742)

@AACR

https://t.co/KnOKljhHNj

[OncoDaily GI @OncoDailyGI]

Tango Therapeutics reported initial Phase 1/2 data for vopimetostat + daraxonrasib in MTAP-deleted, RAS-mutant mPDAC: 92% ORR, 90% 6-month PFS, 100% DCR, and median PFS not reached.

Phase 3 development is planned.

@TangoTxOncology @RevMedicines @MiteshBorad , @FilippoPietran4 @ChiaraCrem1 @GarridoLagunaMD @ChristophSprin3

https://t.co/33yeJM2B8J

#PancreaticCancer #PDAC #Oncology

[OncLive.com @OncLive]

Daraxonrasib monotherapy as a frontline option in metastatic PDAC — phase 1/2 data from AACR 2026 show promising tumor response and disease control in RAS-mutated disease. Read the OncLive® coverage from Eileen M. O'Reilly, MD.

https://t.co/wDjo1i0da3

@EileenMOReilly @MSKCancerCenter #PancreaticCancer #AACR2026 #GIOnc

[𝐄𝐬𝐬𝐉𝐚𝐲 𝐏𝐔𝐑𝐏𝐋𝐄 𝐏𝐔𝐑𝐏𝐎𝐒𝐄 @SJPurplePurpose]

Via https://t.co/e7Zp7Z1M7q

@Eileenmoreilly, an amazing physician/scientist improving outcomes for patients with pancreas cancer. The results of the latest clinical trials mark the dawn of a new era in treatment. Watch the tribute! ⬇️

https://t.co/FCONTxdoCU via @YouTube

[Vumedi Oncology @VuMediHemOnc]

🧬 Could daraxonrasib become the first KRAS-targeted therapy to redefine treatment in metastatic pancreatic cancer?

Dr. Eileen O'Reilly @EileenMOReilly @MSKCancerCenter reviews the practice-changing RASolute-302 data showing significant improvements in survival, response rates, and quality of life versus chemotherapy.

🎥 Watch on #Vumedi: https://t.co/DBjj0eBOQ8

#PancreaticCancer #KRAS